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ABSTRACT
Although cutaneous graft-vs.-host disease (GVHD) has heen noted aft er autologous hematopoietic ce ll trunsp lunra -
tion, intestinal involvement has not hcen well do cumented. \ \ 'e cvaluared 197 pati ents undergoing autologous trans-
plantation for intestinal symptoms; th e source for hematopoietic ce lls was marrow (n=3 2), peripheral blood ste m
ce lls (n = 146), or hoth (n = 19), Patients with persistent nausea , vomiting, and anorexia after day 20 unde rvvent upper
intestinal endoscopy an d mucosal biopsy, Eight patients (4.1 % ) had diffu se ed ema, erythema of gastric mUCOS'l, and
histological evidence of lym phocyti c gast.-itis with focal upoptosis of cryp t epithelial cells-typ ical of th e findings in
acute GVHD. All st ud ies for vira l, fun gal , or bacteria l causes were negative . Two patients showed evidence of
GVHD in skin an d liver, re spectively. All pntients received 1 mg/kg/day of oral prednisone for 10 days; sym pto matic
im provement often occurred wit hin days of therapy o nset. At the end of corticosteroid treatment, complete resolu-
tion of symptoms was seen in all eig ht patients. In one patient, elevated se ru m alka line phosp hatase levels gradually
normalize d over the ensuing 3-4 wecks. " 'h en followed up 3 months aft er treatment, all patients remained sp n p-
tom-free without evidence of recurrent intestinal sym ptoms . \Vc concluded that recipients of autologous hem ato-
po ie tic cc lls ma y develop intestina l sym pto ms caus ed hy a lymphocyt ic gas t ri t is that is typi ca l of acute GVHD.
Patients wit h this syn drome pro m ptly responded to treatment of a sho rt course of prednisone. T he pathogenesis of
gast ric epit helial dumage after autologous transplant is unknown.
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I~TRODUCTION
pi ' .t\ ~u te grnfr-vs.vhosr disease (C VH D), a frequent CO Ill -
cllcatlon of allogeneic marrow transplantation , is clinically
c~a ract e r i 7.ed hy skin, intestinal, and hepatic damage 11,21 . A~ Itlancous GVI ID-lik e svnd rome has also been describ ed
o ow' . , t'f"
Sc Ing nonal logeneie marrow trun splauturiou , a ectlllg
' VCI f't . " ' ,0 C)(, auto logo us and two of I I) syngeneic marrow
c~ten t ~ i,n t w o r c c~ nt se ':ies 1.1 ,41 . T hi s auto logo us
all ID cltnlcally and histologically resembl es GV H D after
sk.ogcncic tran splantation , hut generally involves only the
I Ill , Although intest inal and hepat ic involvement are notlrOIl' , ' . ,Inen t features of auto logo us GV' IJ) [.l-6I, diarrh ea
'/1'
,; '.1' U!ork tras "'/lpp01'/1'I1b)' Ib/' j ;,/lm:'i ll f' '..,'/IIIIs [nun tb.. National lnstitut rs
".J II . " ,~ .
rillib, NII/io llil l CancerInsti tute: C:-,I 570-!, C:-' I SO:!9, and C·I-I77-1S,
and mild liver function ahnormaliries have been descr ibed in
a small number of pati ents 17,HI . Th e developm ent o f
C;VH D after auto logous transplant ation is thought to result
fro m a lack of r cgu lur ion of th e immune response hy a
reconsrin uing immune system 11)1.
\Ve report here a study of eight pat ient s who had enig-
matic nausea, vomiting, and anor exia following auto logous
marrow or peripheral hlood stem cell (PBSC) transplants.
Eaeh patient had a lymph ocytic gastritis histologically indis-
ringu ish nble from acute eV111) and each respo nd ed to
therapy with corticosteroids.
MATERIALS AND METHODS
Patient selection
From ,\·Iay 11)1J.l th rou gh Fch runry IeNS, 11)7 pat ient s
und erwent high -dose cyto reduc tive th erapy followed hy
infusion of autologous marrow (n=32), stem cells (n= 146),
or both (n= 19) at the Fred Hutchinson Cancer Research
Center [10,11]. Underlying diagnoses included non-Hodg-
kin's lymphoma (53), breast cancer (SO), Hodgkin's lym-
phoma (16), acute myelogenous leukemia (19), multiple
myeloma (16), ovarian cancer (6), Ewing's sarcoma (6), acute
lymphocytic leukemia (4), and other solid tumors (27). Con-
ditioning regimens included 12 mg/kg of busulfan (BU), 100
mg/M! of melphalan, and 350-550 mg/M2 of thiotepa
(n=61); 100 mg/kg of cyclophosphamide, 60 mg/kg of
etoposide, and 12 Gy of total-body irradiation (TBI)
(n=55); 12-20 mg/kg of BU and 120-200 mg/kg of
cyclophosphamide (n=30); 14 mglkg of BU, 120 mg/kg of
cyclophosphamide, and 9-10.5 Gy of total-marrow irradia-
tion (n=16); 8 mg/kg of BU, 60 mg/kg of cyclophos-
phamide, and 12 Gy ofTBI (n=15); 14 mglkg ofBU and
400-600 mr/M 2 of thiotepa (n= 11); 1 mg/M2 of etoposide,900 mg/M of thiotepa, and 6 Gy of TBI (n=4); 12 Gyof
total-marrow irradiation (n=4, all receiving second trans-
plants); and 30 mglkg of etoposide and 12 Gy ofTBI (n= 1).
For patients receiving PBSC infusions, the mobilization
regimens included granulocyte colony-stimulating factor
(G-CSF) at 10-32 rg/kg alone (n=57) or after chemo-
therapy with 4 g/M of cyclophosphamide (n=13); 4 g/M2
of cyclophosphamide and etoposide 600 mg/M2 (n=36); 3-4
g/M2 of cyclophosphamide, 400-600 mg/M2 of etoposide,
and 105 mg/M2 of cisplatin (n=28); 4 g/M2 of cyclophos-
phamide and 175 mg/M2 of taxol (n=19); and other regi-
mens (n= 12). More detailed methods and results of these
mobilization schedules have been published [10,11]. The
date of first infusion of PBSCs or marrow was termed "day
0," from which all subsequent events were dated. Post-
transplant patients were followed on a daily basis until they
engrafted and were medically stable, and then were returned
to the care of the referring oncologist.
Evaluation of gastrointestinal symptoms
All patients who developed persistent gastrointestinal com-
plaints after transplant were evaluated by the Gastroenterol-
ogy/Hepatology Section at the Fred Hutchinson Cancer
Research Center. Evaluation consisted of patient histories
(particularly as related to current medications and risk factors
for herpesvirus infection), physical examination, laboratory
tests for liver and pancreatic disease, and imaging tests (ultra-
sound, computed tomography [eT] X ray) if indicated [2].
Esophagogastroduodenoscopy (EGD) was performed on all
patients who had persistent nausea, vomiting, anorexia,
abdominal pain, gastrointestinal bleeding, or difficulty swal-
lowing. Our endoscopic protocol for transplant patients has
been described [12,13]. Biopsy specimens were routinely
taken from four sites in the gastric antrum plus any other
mucosal area that appeared abnormal. Biopsy specimens
were placed in B5 fixative for histology (hematoxylin-eosin,
methenamine silver, and Brown-Hopps tissue Gram stains);
in urea-containing medium for detection of Helicobacter pylori
(CLO test, Delta West, Bentley, W; Australia); and in veal
infusion broth for viral culture. Viral culture methods includ-
ed both conventional fibroblast cell culture for microscopic
examination of cytopathic alterations and centrifugation cell
culture for rapid diagnosis of cytomegalovirus by indirect
immunofluorescence [14].
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Diagnosis of GVHD
Diagnosis of acute intestinal GVHD required all of 0e
following elements: upper intestinal endoscopy show:~f.
abnormal mucosa in the stomach or duodenum [12,15, "
histological findings in biopsy specimens of the gastrl~
mucosa, showing apoptotic crypt epithelial cells and crypt~~].
dropout with or without focal lymphocytic infiltrates [16- ,~
and negative results from viral cultures of gastric biopsyspe~
mens, histologic stains of gastric biopsy specimens for bac,terla
and fungi (i.e., methenamine silver and Brown-Hop~s ossu~
Gram stains),histological evaluation for viral cytopathice~ec
and the CLO test for Heliccbacter pylori (Delta West) [13,1 .
RESULTS
Patients evaluated .
We evaluated 31 patients who had persistent gasU:0I~~
testinal symptoms after transplant. Sixteen of these p~oen
underwent intestinal endoscopy with mucosal blOP~~
including 14 who had upper endoscopic examinations an
who had both upper endoscopic and colonoscopic.
Patients with lymphocytic gastritis resembling GVHD I .
Characteristics. Eight patients with biopsy-prove~ ytUe
phocytic gastritis resembling GVHD who had no eV1den~7
of gastrointestinal infection were identified from among. 1d.
patients who had received autologous transplants, an rn s
dence of 4.1 % (Table 1). Seven had received autologa2)PBSC transplants for non-Hodgkin's lymphom.a (n ==fa;
breast cancer (n=4), and ovarian cancer (n= 1); reglI~enf •
PBSC harvest are shown in Table 1. One patient Wlth rmnphoma had received autologous marrow. Seven had bfe
conditioned with 12 mg/kg of BU, 100 mg/M2 of melpht;o
and 500 mg/M2 of thiotepa; and one with 14 mglkg 0 •
and 550 mg/M2 of thiotepa. Dominant symptoms were naus
sea, vomiting, and anorexia leading to significant weight ~sn
and a decreased sense of well-being. Diarrhea (mor~ t ae
three loose stools a day) and abdominal pain were seen in five
and three patients, respectively.The diarrhea was not sever
in any patient, but was characterized by intermittent wa~e~
stools accompanied by crampy abdominal pain. One p~oefn
(unique patient number [UPN] 8803) also had dysphagta. s
seven of eight patients, the onset of intestinal sympta~)
occurred between day 20 and 50. One patient (UPN 80 t
had continuous, unabated nausea, gagging, and retching t~.
dated from the conditioning chemotherapy, and was a f
lowed by the development of vomiting at day 23. Onset rs
these symptoms occurred on day 0 (Table 1). Two.wee It
posttransplant, another patient (UPN 7844) had a skin ras•
and a skin biopsy specimen consistent with GVHD. Cut~"
neous manifestations of GVHD were absent in the other 51
patients. Concomitant with her gastrointestinal symptoJ?~
another patient (UPN 8499) showed a 5- to 6-fold e1evao?It
of serum alkaline phosphatase, which was consistent w
b
l.t
hepatic GVHDj serum aminotransferase enzymes, biliru In,
abdominal ultrasound, and CT were normal. l-
Endoscopic and histological findings. Endoscopic abn~rlD~e
ities included diffuse edema and patchy erythema tn. t s
prepyloric gastric antrum. Frank erosions or ulceratiOns
were not present. In one patient (UPN 8855), these gras,
changes extended into the gastric body and fundus. Mucosa
AutologousGastric GVHD
Table I. Clinicalfeatures of 8patients with Iymph0'Yticgastritis resembling graft-vs.-host disease
PBSe mobilizationb Gastrointestinal symptoms
UPN" and pretransplant Day of onset! Nauseaor
-
Age Sex Diagnosis conditioning regimens· Type of transplant d day of endoscopy vomiting Anorexia Diarrhea Pain
7844 40 M Lymphoma N/A Autologous marrow 35/43 Y Y Y Y
7853 BU, Mel, TT58 F Lymphoma cr, etoposide, G·eSF Autologous PBSe 30/239 y Y N N
8097 BU, Mel, TT64 F Breast cancer ey, taxol, G·eSF Autologous PBSe 0/33 y Y Y N
8499 BU, TT50 F Breast cancer G·eSF Autologous PBSe 30/50 y Y N N
8639 BU, Mel, TT57 F Breast cancer G·eSF Autologous PBSe 50/69 y Y Y Y
8803 BU, Mel, TT53 F Ovariancancer cr, taxol, G·eSF Autologous PBSe 40/69 y Y N N
885S BU, Mel, TT50 F Lymphoma cr. G·eSF Autologous PBSe 25/33 y Y Y Y
9002 BU, Mel, TT65 F Breast cancer ey, etoposide, c1splatln Autologous PBSe 23/44 y Y Y N
---
BU, Mel, TT
:Unique patientnumber.
?cloPhosphamide (CY), 3-4 g/M 2; etoposide, 400-600 mg/M2; cisplatin, 105 mg/M 2; taxol, 175 j.Lg/M2; granulocyte colony-stimulatingfaaor [G-CSF},
, ()..16 ILg/kg.
d~~SMel, IT; 12 mg/kg ofbusulfan, 100 mg/M2 ofmelphalan, and 500 mg/M 2 of thiotepa: BU, IT; 14 mg/kg ofbusulfan and 500 mg/M2 thiotepa.
C, Peripheral blood stemcells.
~~opsy .from the gastric antrum revealed a picture of Iym-[Itytic gastritis consistent with acute GVHD (Fi.g. lA)·
s -20]. Individual epithelial cell necrosis (apoptoslS) was
Iee~ at the base and sides of crypts (Fig. IB). Infiltration of
parnIna propria and crypt epithelium by lymphocytes was
/esent to a variable extent. None of the patients had evi-
vjenfe of infection with viruses, bacteria, or fungi, and no
ra cytopathic effect was seen histologically.
o Response to therapy. Before endoscopic diagnosis and with-
a::t s.uccess, patients had been treated empirically with
v ~clds, Il2 receptor antagonists, sucralfate, omeprazole, and
aaf1? US antiemetics including antihistamines, benzodi-
;epInes, and serotonin antagonists. Three patients had been
heated with a prokinetic agent (cisapride) and two patients
f ad been prescribed amoxicillin, metronidazole, omeprazolet ~ presumed but unproven Helicobacter pylori infection. Fol-
pO~Ing histological diagnosis of lymphocytic gastritis, all
~tients received 1 rug/kg/day of oral prednisone for 10 days,
d en O.S mg/kg/day for 3 days, then 0.25 mglkg/day for 3
~y~, ~nd then the prednisone was discontinued. Sympto-
abc Ilnprovement often occurred within days of therapy
onset. At the end of steroid treatment, complete resolution of
~Ptoms was seen in all eight patients. In one patient (UPN
I 99)who also had simultaneous serum alkaline phosphatase~ evation, the alkaline phosphatase level gradually normalized
ver the ensuing 3-4 weeks. When followed up at 3 monthsa~er treatment, all remained symptom-free without evidence
o reCUrrence. Endoscopy wasnot repeated in any patient.
~Iagnoses In 23 patients not classified as having
Yrnphocytlc gastritis
t Among 23 other patients who were evaluated for persis-
ent gastrointestinal symptoms, there were nine whose
I1I1&MT
symptoms were attributed to regimen-related toxicity
involving the intestinal mucosa or liver; five whose symp~
toms were caused by infection (cholecystitis [2], typhlitis
caused by a clostridial organism [1], phlegmonous gastritis
[I], and enterococcal sepsis [1]); one each with eosinophilic
gastritis (probably drug-related), gastric antral vascular ecta-
sia, and recurrent malignancy; and six with unexplained
symptoms. This latter group is interesting because they
probably also had lymphocytic gastritis that resembled
GVHD, but there was a reluctance on the part of patholo-
gists and treating physicians to make an unequivocal diagno-
sis of this disease; their symptoms persisted for many weeks
until death (four patients) or treatment with prednisone for
another indication (two patients).
DISCUSSION
Eight patients developed persistent unexplained nausea,
vomiting, and anorexia following autologous transplant with
marrow or PBSCs. We believe that these gastrointestinal
symptoms were because of a lymphocytic gastritis indistin-
guishable from acute GVHD for several reasons: 1) these
symptoms are typical of acute GVHD in allogeneic marrow
recipients [12,15,16,21]; 2) empiric antiemetic therapies
failed to have an impact on the symptoms; 3) no infections
could be identified; 4) both the endoscopic and histologic
appearance of the gastric mucosa were characteristic of
acute GVHD [16-20]; and 5) treatment with a short course
of prednisone resulted in cessation of symptoms.
While it is common for patients to have nausea, vomit-
ing, anorexia, and diarrhea during and after high-dose
cytoreductive therapy, these symptoms and the histologic
abnormalities in the intestinal mucosa caused by such thera-
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Figure I. Photomicrographs of gastric biopsy specimens, demonstrat ing alterat ions characteristic of acute graft-vs.-host disease .' 1"
A (UPN 8855, l U rE X 500) , lymphocytic infiltration ofthe lamina propria and 1111/COSIII crypts. Note tbe drop-out ofepitbelia! (I'llv ill illl'ol,,1'Ii <7Ypu. B (VI'S i SH !Iv .
X 800), focal epitbelial cell apoptosis is seen fit the base ofa gastric C"lypt.
py usually resolve by day 20 posttransplant [22,23]. Some
regim ens, how ever, can produce mu cosal dam age that is
mor e severe and pro longed than is normal [10,24]. For allo-
genei c marrow recipi en ts, the mean day of onset of acute
GVHD is day 19 [25]. The presence of persistent nausea,
vomiting , and anorexia after day 20 in an allogeneic marrow
recipient points to eithe r acut e G VH D of th e upp er gut,
herpesviru s infecti on , or m edi cati on -induced nau sea
[12,15,16,2 1]. Gastric GVH D is by far the most commo n
cause for enigmatic nausea and vomiting in allogeneic mar -
row transplant patien ts who arc beyond day 20, accounting
for 81-86% of cases in a recent pro spective study [2 1]. Her -
pes simplex virus and cyto megalov irus ar e now unusual
causes of these symptoms because of the use of prophylactic
antiviral agents [26]. No netheless, we looked for these virus-
es in th e auto logous gra ft recipi ent s reponed her e and
found non e. T his is importan t because apopto ric cells, the
hist ologic ha llmark of immun e-m edi ated epithel ial ce ll
injury, can be seen occasionally in the intestinal epithelium
infected by cytomegalovirus [1 4,27].
A syndrome resemblin g mild G VH D has been reported
in approximately 8% of patients receiving auto logous or syn-
geneic bone marrow transplantati on [4]. In these patients, a
maculopapu lar rash, clinically and histologically indistinguish-
able from allogeneic GV H D, appears usually between the first
and third week after transplant. More recently, G VH D was
induced delib erately by treatin g patients with cyclospor ine
following autologous marrow infusion to explore the potential
therapeuti c efficacy of a graft-vs.vrum or effect 16,7,2H] . In
these patien ts, a mild form of GV}-( D that was confined to
the skin resolved spontaneously or after a short course of cor-
ticosteroid tr eatm ent. In a sma ll series that reported on 4
patients with GVH D after syngeneic bone marrow transplan-
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ration [8], one had concomitant diarrhea and three had c1e~a ti
I . t' I I '1' I ' 11tCS[lJ1;!ec serum aminotrans erase enzymes am II iru 1111. I . I
and hepatic involvem ent by c;VI'1D was sugges ted by tI e
I I I · I . I' " I . 'd Ouraut iors, JUt no 11StO0gle l con fi rm at io n was o ltall1e . . I
I I · · I I" f'(II' '1UtO •cases ( emonstra te t mt gastrIc epit ie rum ISa target " "
ogous G VH D. T he upper gastro intestinal findings were .I ~O ,
I I . . f I . I I I . I ) I'e \' I OU~at et events in SIX o r elg it panenLs w 10 iac ne it icr I
nor ongoing skin or liver manifestations of GV H D. s
In h~lInan .~n d rod.em studies, i nd ucti ~ln of a u.t~I,I(~g.~;; ~
G VJ-[ D ISassociat ed with the emerge nce of cvtoWX IC I c )
that recogni ze class II human leuko cyte ;1/; tigens ([-ILAs
[9,29]. Ablation of a T cell- de pende nt regulatory ,n ech ;~ ~
nism in the peripheral lymphoid compartme nt by h i g~) - (h::~
che mo the rapy or T BI allows furth er expa nsion of the.,.
autoreactive T cells 130- 32]. A clear explanation for the p~~ ,
dominance of skin involvement is lacking. As shown in r 1I ~
study, sym ptoma tic and histologic involvement of the .s t O I,~I~
ach by a GVI-l D-like gastr it is app ears to he rar e; It \1 ,1 ~
observed in < 5'1" (H of )97) of our cohor t. EndoscoPY \\, ;I ~
f I . I I I . I . ri c thu~per ormec 111 on V t rose w 10 rem um cc symptoma IC,
I . . I ' I I . . I I . . soll1et ie exac t II1 CI< ence canno t ie ncrcrnu ner leC;1l1Se . ' ..1
patien ts may he mini mally sym pto ma tic despite histologl(,I.
. I I I I I ' . I . sonllII1VO vement. nceer ear y 111 our experIence, t ier e was . ' .
I I f rreati I " • '11t t111 ~re ucrance on t ie part or treatin g p 1yslclans to acce f
diagnosis or to consider endoscopic biopsy in recipientS C.l .
autologous hemotopoietic cells. In our series, svmptOlna[l(
. . f" I ' . I' .ceivedgast ri tis was seen as reljuent y 111 patien ts \\' 10 re '.
PBSCs (7 of 146) as in those who received auto logouS nl;\1
row infusion ( I of 32; P > 0.9). T hese eight patients nrc no~
di.ffer ent from th ose ,who did not . dev~ l o p thi.s sy n d :'o ~ ~~
With regard to type 01 cance r, conditioning regllnen, l .n., _
harvest protocol, days between PBSC harvest and relldu
sion, or conco mitant lise of growth factors (data not shol\'n).
Autologous Gastric GVHD
tr Even though a large number of autologous marrow
~nsplantshave been carried out at our center over the last
sibrdecades, we had not recognized this syndrome. It is pos-
pi e tI:at recently introduced methods of autologous trans-
i antat:J.?n may be responsible; for example, new condition-
p~ regImens, PBSC harvest regimens, and different lym-
III oeyt:e profiles after the infusion of autologous PBSCs vs.
s ~rrow ,Progenitor cells. Melphalan and thiotepa may cause
Uu stant:J.al gastrointestinal mucosal toxicity [10,11], and the
~e ~f these agents in combination with BU may play an eti-
o oglc role in this syndrome by altering epithelial cells and
creat' di dIn~ targets for subsequent T lymphocyte-me late~P~PtOSIS. Although there was no apparent difference in the~cIdence of this syndrome between recipients of PBSCs vs,
..,arrow th b f nati . .
, e num er 0 patients recervmg marrow was com-~~~tively small. Seven of our eight patients had received
I Cs but One recipient of autologous marrow did have
YInphocytic gastritis consistent with GVHD.
f GVHD does not usually enter the differential diagnosis~ anorexia, nausea, and vomiting following autologous
dansplant because of a common belief that visceral GVHD
aoes not occur after autologous transplantation. This belief
Ppears untrue. Physicians caring for patients after autolo-
gous transplant should be aware of gastric GVHD as a
POtential cause for persistent intestinal symptoms.
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